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micrometastatic LN in 3 patients, and 4) weak FDG uptake in mediasti-
nal ipsilateral macrometastatic LN in 5 patients. 
Conclusions: Before therapeutic decision, an abnormal mediastinal 
FDG uptake must be conﬁrmed pathologically. In certain situations, 
SEM is also indicated when there is no abnormal uptake in the medias-
tinum. 
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Objective: Neuroendocrine (NE) lung tumors consist of typical carci-
noid (TC), atypical carcinoid (AC), large cell neuroendocrine carci-
noma (LCNEC) and small cell carcinoma (SCLC). The determinant of 
FDG uptake for NE lung tumors has not been well elucidated. The aim 
of the present study is to investigate the relationship of FDG uptake and 
glucose transporter type 1 (Glut-1) expression in NE lung tumors. 
Methods: NE lung tumor patients (n=32; age, mean ± s.d.=67.8±10y; 
male:female=28:4) who had underwent F-18 FDG-PET before treat-
ment were enrolled. There were 1 TC, 3 AC, 5 LCNEC, and 23 SCLC. 
FDG uptake was represented by maximum standardized uptake value 
(maxSUV). The parafﬁn sections of the tumor tissues were immunos-
tained for Glut-1 (Neomarker, 1:50). The relation of FDG uptake and 
Glut-1 expression was assessed by Pearson correlation analysis. 
Results: The maxSUVs of all NE lung tumors ranged from 0.6 to 29.5 
(mean±s.d.=7.7±5.4), whereas percentage Glut-1 expression ranged 
from 0 to 100% (18±24%). MaxSUVs of all NE lung tumors were 
signiﬁcantly correlated with percentage Glut-1 expression (r=0.6471, 
p=0.0001). In subgroup analyses, maxSUV was also signiﬁcantly cor-
related with Glut-1 expression in SCLC (n=23, r=0.6189, p=0.0016) 
and in non-small cell NE lung tumors (n=9, r=0.7039, p=0.0343). 
The maxSUV and the percentage Glut-1 expression were 1.7±2.0 and 
5.0±0.0%, 7.9±3.2 and 35.0±32.4%, and 7.6±3.7 and 12.6±14.1% 
for AC, LCNEC, and SCLC, respectively. MaxSUV of SCLC was 
signiﬁcantly higher than that of AC (p=0.007), but percentage Glut-1 
expression was not signiﬁcantly different among AC, LCNEC, and 
SCLC (p>0.05). One TC case had a maxSUV of 29.5 and 100% Glut-1 
expression.
Conclusions: In NE lung tumors, the maxSUV on FDG-PET was 
highly correlated with Glut-1 immunostaining positivity. This result 
suggests that Glut-1 expression is one of the determining factors of 
FDG uptake in NE lung tumors.
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Aims: To investigate whether the addition of FDG-PET to standard 
evaluation procedure alters tumour stage, mainly by detection of occult 
distant metastases, and thus has an impact on the ﬁnal treatment in 
patients planned for chemo-radiotherapy. 
Material and Methods: In June 2003 we added FDG-PET to conven-
tional evaluation of lung cancer in patients with NSCLC planned for 
high dose radiotherapy with concomitant chemotherapy. 
The routine evaluation consisted of clinical examination, chest x-ray, 
CT-scan of thorax and upper abdomen, bronchoscopy and comple-
mentary imaging as needed. The evaluation of the clinical data and 
the CT-scan was performed in a conference with the participation of 
at least one experienced pulmonary oncologist and an experienced 
chest radiologist. Based on the routine evaluation, totally 53 patients 
(32 men, 20 women) were in stage IIB-III and thus were planned for 
concomitant chemo-radiotherapy. These patients underwent FDG-PET 
as the ﬁnal part of the staging procedure.
Results: In a total of 53 patients, 10 patients (19%) were found to 
have distant metastases undiagnosed by routine evaluation. The initial 
management plan was altered in 8 cases (15%). 
Conclusion: Adding FDG-PET to routine clinical evaluation is justi-
ﬁed also in this clinical setting.
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Background: Papillary adenocarcinoma (PA) is a distinct histological 
subtype of adenocarcinoma of the lung, but its radiological ﬁndings 
have been rarely reported. Histologically, the micropapillary compo-
nent is well known characteristic feature of PA and has been found to 
be a distinct pathologic marker for poor prognosis. The purpose of this 
study is to evaluate characteristic Computed Tomographic (CT) ﬁnd-
ings of adenocarcinoma with micropapillary component (PA pattern). 
Methods: From January 2000 to February 2006, 1078 consecutive 
patients were conﬁrmed adenocarcinoma of the lung by histopathology, 
including 45 PA pattern (M:F=24:21, mean age, 59yrs). Chest CT was 
reviewed as consensus reading by two radiologists. The CT ﬁndings 
such as size, number, margin, character (consolidation or inﬁltration, 
cavity) of tumor, the presence of ground-glass opacity (GGO), spicula-
tion, lobulation, air-bronchogram, bubble lucency, and pleural tagging 
were assessed. 
Results: Dominant CT ﬁnding of PA pattern adenocarcinoma was soli-
tary mass or nodule (n=35, 78%). Another ﬁnding is central mass (n=9, 
20%) or inﬁltration (n=3, 7%). Spiculation (n=20, 44%) and lobulation 
(n=25, 56%) are common characteristics of nodules, however, GGO 
(n=9, 20%) and air-bronchogram or bubble lucency (n=12, 27%) is less 
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common. At the time of diagnosis, intrapulmonary metastases were 
found at seven cases (16%) 
Conclusion: Predominant radiologic ﬁnding of PA pattern adenocar-
cinoma is solitary nodule or mass with lobulation and ﬁne speculation. 
Secondary dominant CT feature is central mass or inﬁltration which are 
uncommon in adenocarcinoma. Further investigation is necessary to 
correlate pathologic ﬁndings of these two subtypes. GGO, air-broncho-
gram and consolidation is less common CT ﬁndings. Although it is not 
speciﬁc, there are several characteristic CT features to suggest subtype 
of adenocarcinoma with micropapillary pattern.
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Background: In recent years, clinical use of high-resolution computed 
tomography (CT) has greatly advanced the diagnosis of small lesions of 
the peripheral lung. Such small lesion is often associated with ground-
glass opacity (GGO) in CT ﬁndings. The important issue in the man-
agement of small lung carcinoma, especially those showing pure GGO, 
is the dormant nature of the tumor. Although it has been suggested 
that the adenoma-carcinoma sequence also applies to tumorigenesis in 
adenocarcinoma of the lung, no persuasive data have been presented 
about the percentage of pure GGO lesions that are indolent over a 
long clinical course or the percentage of GGO lesions that progress to 
become solid lesions. The timeframe for small GGO lesions to progress 
to solid tumors is also unclear. To avoid an overdiagnosis bias and un-
necessary surgery, it is important to elucidate the natural history of the 
small lung lesions showing GGO features.
Methods: We investigated clinicopathological ﬁndings of 18 patients 
with small peripheral lung lesions showing pure GGOs or part-solid 
GGOs deﬁned with CT and retained for more than six months. After 
long-term observation, three of 18 patients underwent pulmonary resec-
tion, and 15 are currently being followed. 
Results: The patients comprised six men and 12 women, ranging in 
age from 37 to 80 years. The median follow-up period was 25 months, 
ranging from 6 to 72 months. The size of lesion at the time of ﬁrst 
presentation was 5 to 22 mm in largest diameter. There were 12 patients 
with solitary lesion and six had multiple lesions raging in number 2 to 
20. Of the 18 patients, 10 showed pure GGO on CT and 8 with part-
solid GGO type. During follow-up, the size of lesion showed no change 
(±1mm) in 13 (72%) patients, increased slightly (up to 5mm) in three 
(17%), and increased by more than 5mm and showed new lesions in 
two (11%). Of the 10 patients with pure GGO, 9 showed no change in 
size of the lesion. Three patients underwent limited pulmonary resec-
tion (segmentectomy in two patients and wedge resection in one) with 
negative surgical margin. Of them, two patients had adenocarcinoma 
and one bronchioloalveolar carcinoma. There was no clear tendency 
between the degree of size change and histology. All patients are alive.
Conclusions: Previous reports have often suggested that the manage-
ment of GGO lesions should differ from the management of small, 
peripheral, noncalciﬁed solitary nodules showing soft-tissue density. 
Our data suggest that some small lung lesions, especially showing pure 
GGO, will never progress to clinical disease and might be overdiag-
nosed.
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Objective tumor response is a common endpoint in daily practice as 
well as in clinical trials to evaluate the efﬁcacy of anti-cancer agents. 
To maintain uniformity we are following the consensus statements 
for long times. The general sense suggests that any tumor response is 
always three dimensional. However by the application of the math-
ematical models we gradually reduced it to two dimensions (WHO). 
However progress in imaging technology mandated new methodology 
to evaluate response to treatment. One among such is the Response 
Evaluation Criteria in Solid Tumors Group (RECIST) guidelines using 
unidimensional measurement. Theoretically, the simple sum of the 
maximum diameters of individual tumors is not accepted by many on-
cologists as a representative of cell kill than is the sum of the bidimen-
sional products and they prefer 3D. many previous trails have resolved 
this issue and presently the RECIST is considered as gold standard. 
However the practice of radiologists is not uniform and therefore we 
thought of comparing WHO and RECIST criteria 
Methods: A total of 48 previously untreated patients with locally 
advanced or metastatic NSCLC during 2004 to 2006 with an ECOG 
performance status (PS) scale of ? 2 were included. Patients received 
either a combination of Gemcitabine and Cisplatin; Gemcitabine and 
Carboplatin or cisplatin with etoposide. Gemcitabine was given at a 
dosage of 1250mg/m2 on days 1and 8 of a 3 weekly cycle, while Cis-
platin was given at 75-100mg/m2 and Carboplatin at an AUC of 6 once 
every three weeks. Etoposide was given as 100mg/m2 infusion per day 
over 3 days. 
The treatment arms were based on the socioeconomic status of the 
patient.The responses were assessed with either a chest X ray or a CT 
scan again based on the economic status and the method was main-
tained constant all through the study. Response was assessed as per the 
RECIST criteria as well as WHO criteria. Assessment was done at end 
of every 2nd cycle and conﬁrmed after 4 weeks of initial response. The 
tests repeated if clinically indicated.Our study shows the wide discrep-
ancy between the WHO and the RECIST assessment systems and thus 
the need to evaluate on similar scales.
The ideal system seems to be the one that would simply look at the 
volume in a 3 dimensional way.
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The International Staging System,is currently based on prognostic 
data, mainly issued from surgical series. It is generally considered that 
locally advanced non-small cell lung cancers have to be treated by 
multimodal approaches, at least including induction or adjuvant chemo-
therapy, because their propensity to distant metastatic spreading. Pre-
sumably those patients without N2 or N3 lymph node involvement will 
be referred to surgery, because disease progression is more expected at 
the locoregional level. Authors retrospectively reviewed 392 patients 
